ONTX has been the topic of several other research reports. HC Wainwright set a $6.00 price target on shares of Onconova Therapeutics and gave the stock a buy rating in a report on Thursday, January 4th. Zacks Investment Research downgraded shares of Onconova Therapeutics from a hold rating to a sell rating in a report on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $8.00.
Onconova Therapeutics (ONTX) opened at $1.07 on Thursday. Onconova Therapeutics has a fifty-two week low of $0.95 and a fifty-two week high of $3.88. The firm has a market cap of $19.82, a P/E ratio of -0.38 and a beta of 0.22.
In related news, major shareholder 683 Capital Management, Llc acquired 200,000 shares of the stock in a transaction on Thursday, February 8th. The shares were acquired at an average price of $1.04 per share, for a total transaction of $208,000.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 13.30% of the company’s stock.
A hedge fund recently raised its stake in Onconova Therapeutics stock. Vanguard Group Inc. grew its stake in Onconova Therapeutics Inc (NASDAQ:ONTX) by 58.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,940 shares of the biopharmaceutical company’s stock after purchasing an additional 32,418 shares during the period. Vanguard Group Inc. owned about 0.93% of Onconova Therapeutics worth $190,000 at the end of the most recent quarter. 12.72% of the stock is owned by institutional investors and hedge funds.
About Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.